Home / Pharmaceuticals / Cervical Cancer Treatment Market By Product (Chemotherapy, Targeted Therapy, Surgical Procedure, Radiation Therapy and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Cervical Cancer Treatment Market By Product (Chemotherapy, Targeted Therapy, Surgical Procedure, Radiation Therapy and Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Published: Jan 2019 | Report Code: 59521-01-19

The cervical cancer treatment market will be highlighting excellent growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2018 to 2026. Cervical cancer occurs in women in age group ranging from 14 to 49 years. The human papillomavirus (HPV) is the main causative agent for the occurrence of cervical cancer which is sexually transmitted. Cervical cancer can be prevented by performing early screening test and vaccination using Gardasil against HPV infection.

It is quite obvious that generic market is having the major economic share in the cervical cancer treatment market, however the advent of biologics in the form of monoclonal antibodies and biosimilars has resulted in a major paradigm shift in the treatment regimen. Z-100 and ADXS11-001 are currently in the phase III clinical trials being tested for drug safety and efficacy in the treatment of cervical cancer.

Market Synopsis

Cervical Cancer Treatment Market

Get a sample copy for more information

"Affordable reimbursement scenario drive the chemotherapy market growth"

Currently, chemotherapy is reigning the product segment for cervical cancer treatment market. Drugs such as cisplatin, carboplatin, paclitaxel, doxorubicin and gemcitabine are employed for the treatment of cervical cancer in advanced stages. Radiation therapy such as external beam therapy and brachytherapy are given concurrently with chemotherapy in some stages of cervical cancer to give excellent synergistic effect. The side effects associated with both the therapy are severe thereby leading to the need for targeted drug therapy. Avastin (bevacizumab) and Keytruda (pembrolizumab) etc. are used in cancer immunotherapy which possesses impressive clinical efficacy, dose tolerance and patient compliance. Targeted drug therapy will be the fastest growing market during the forecast period owing to the strong drug pipeline in phase III clinical trials such as nimotuzumab and Atezolizumab. Cervical hysterectomy involves the removal of uterus, cervix and sometimes the fallopian tubes in women suffering with early stage cervical cancer.

Cervical Cancer Treatment Market 

Get a sample copy for more information

"Increasing number of patients screened for cervical cancer drive the market growth in North America"

North America is the clear leader for the geographical segment in the cervical cancer treatment market. As per the latest research findings of American Cancer Society, in 2019, approximately 13,170 new cases were diagnosed for cervical cancer and around 4,250 women will die from cervical cancer. Rising prevalence of cervical cancer and increasing public health awareness resulting in early screening and medical intervention drives the market growth in North America. According to the facts presented by World Health Organization (WHO) it is estimated that in 25,000 women for the European region will die from cervical cancer. Existence of major players such as Merck & Co., Inc., F.Hoffman La-Roche AG, GlaxoSmithkline Plc., etc. propel the cervical cancer market growth in the European region. Asia Pacific will register outstanding growth during the forecast period owing to the proactive government policies in early screening and medical intervention to curb the mortality related to cervical cancer and presence of huge generic market.

Cervical Cancer Treatment Market

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The market is subsegmented by product and geographical segment.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 By Product (2016–2026; US$ Mn)
  • Chemotherapy
  • Targeted Therapy
  • Surgical Procedure
  • Radiation Therapy
  • Others
    o Pipeline Analysis
       Phase III Drugs
       Z-100
       ADXS11-001
       Nimotuzumab
       Atezolizumab
    o Tabular Representation of Drug Pipeline in Phase II and I

 Geography Segment (2016–2026; US$ Mn)
 • North America (United States and Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

Biopharmaceutical companies having a strong foothold in the cervical cancer treatment market are, Allergan, Plc., Biocon Ltd., CooperSurgical, Inc., Eli Lilly & Company, F.Hoffman La-Roche AG, GlaxoSmithkline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Varian Medical Systems, Inc. 

Key questions answered in this report

  • What are latest market trends prevailing in the cervical cancer treatment market?
  • Which biopharmaceutical companies are competing in the cervical cancer treatment market?
  • What are the clinical manifestations occurring in the cervical cancer?
  • What are the screening test performed and treatment regimen adopted for the treatment of cervical cancer?
  • What led to the rise of targeted therapy and how will it be performing during the forecast period from 2018 to 2026?
  • What are the major attributes responsible for the dominance of North America in the cervical cancer treatment market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global CCT Market Portraiture
2.2. Global CCT Market, by Product, 2017 (US$ Mn)
2.3. Global CCT Market, by Geography, 2017 (US$ Mn)

Chapter 3. Cervical Cancer Treatment (CCT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global CCT Market, by Key Players, 2017

Chapter 4. Global Cervical Cancer Treatment (CCT) Market, by Product
4.1. Overview
4.2. Chemotherapy
4.3. Targeted Therapy
4.4. Surgical Procedure
4.5. Radiation Therapy
4.6. Others
4.7. Pipeline Analysis
4.7.1. Phase III Drugs
4.7.1.1. Z-100
4.7.1.2. ADXS11-001
4.7.1.3. Nimotuzumab
4.7.1.4. Atezolizumab
4.7.2. Tabular Representation of Drug Pipeline in Phase II and I

Chapter 5. Global Cervical Cancer Treatment (CCT) Market, by Geography
5.1. Overview
5.2. North America CCT Market Analysis, 2016 – 2026
5.2.1. North America CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.2.2. North America CCT Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe CCT Market Analysis, 2016 – 2026
5.3.1. Europe CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.3.2. Europe CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific CCT Market Analysis, 2016 – 2026
5.4.1. Asia Pacific CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America CCT Market Analysis, 2016 – 2026
5.5.1. Latin America CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.5.2. Latin America CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East and Africa CCT Market Analysis, 2016 – 2026
5.6.1. MEA CCT Market, by Product, 2016 – 2026 (US$ Mn)
5.6.2. MEA CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Allergan, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Biocon Ltd.
6.3. CooperSurgical, Inc.
6.4. Eli Lilly & Company
6.5. F.Hoffman La-Roche AG
6.6. GlaxoSmithKline, Plc.
6.7. Ethicon, Inc.
6.8. Merck & Co., Inc.
6.9. Teva Pharmaceutical Industries Ltd.
6.10. Varian Medical Systems, Inc.

* CCT - Cervical Cancer Treatment

FIG. 1 Cervical Cancer Treatment (CCT) Market: Research Methodology
FIG. 2 CCT Market Segmentation
FIG. 3 Global CCT Market, by Product, 2017 (US$ Mn)
FIG. 4 Global CCT Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2017
FIG. 6 Competitive Analysis: Global CCT Market, by Key Players, 2017
FIG. 7 Global Chemotherapy Market for Cervical Cancer Treatment, 2016 – 2026 (US$ Mn)
FIG. 8 Global Targeted Therapy Market for CCT, 2016 – 2026 (US$ Mn)
FIG. 9 Global Surgical Procedure Market for CCT, 2016 – 2026 (US$ Mn)
FIG. 10 Global Radiation Therapy Market for CCT, 2016 – 2026 (US$ Mn)
FIG. 11 Global Other Products Market for CCT, 2016 – 2026 (US$ Mn)
FIG. 12 U.S. CCT Market, 2016 – 2026 (US$ Mn)
FIG. 13 Canada CCT Market, 2016 – 2026 (US$ Mn)
FIG. 14 U.K. CCT Market, 2016 – 2026 (US$ Mn)
FIG. 15 Germany CCT Market, 2016 – 2026 (US$ Mn)
FIG. 16 Rest of Europe CCT Market, 2016 – 2026 (US$ Mn)
FIG. 17 China CCT Market, 2016 – 2026 (US$ Mn)
FIG. 18 Japan CCT Market, 2016 – 2026 (US$ Mn)
FIG. 19 Rest of Asia Pacific CCT Market, 2016 – 2026 (US$ Mn)
FIG. 20 Brazil CCT Market, 2016 – 2026 (US$ Mn)
FIG. 21 Mexico CCT Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Latin America CCT Market, 2016 – 2026 (US$ Mn)
FIG. 23 GCC CCT Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of MEA CCT Market, 2016 – 2026 (US$ Mn)

TABLE 1 Global Cervical Cancer Treatment (CCT) Market Portraiture
TABLE 2 Global CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 3 Global CCT Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 4 North America CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 5 North America CCT Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 6 Europe CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 7 Europe CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 Asia Pacific CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 Latin America CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 11 Latin America CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Middle East and Africa CCT Market, by Product, 2016 – 2026 (US$ Mn)
TABLE 13 Middle East and Africa CCT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Allergan, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Biocon Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 CooperSurgical, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 F.Hoffman La-Roche AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 GlaxoSmithkline, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Ethicon, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Varian Medical Systems, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients